{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:21:43Z","timestamp":1776709303439,"version":"3.51.2"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T00:00:00Z","timestamp":1269561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1000720","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T22:17:38Z","timestamp":1269555458000},"page":"e1000720","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV"],"prefix":"10.1371","volume":"6","author":[{"given":"Max","family":"von Kleist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Menz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2010,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team.","volume":"337","author":"SM Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/314948","article-title":"A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.","volume":"180","author":"M Hirsch","year":"1999","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35073673","article-title":"HIV chemotherapy.","volume":"410","author":"DD Richman","year":"2001","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/344959","article-title":"Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.","volume":"35","author":"J Kulkosky","year":"2002","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1086\/344357","article-title":"Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.","volume":"186","author":"J Kulkosky","year":"2002","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.","volume":"278","author":"D Finzi","year":"1997","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.","volume":"278","author":"JK Wong","year":"1997","journal-title":"Science"},{"key":"ref8"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-6405-4-11","article-title":"Predictors of disease progression in HIV infection: a review.","volume":"4","author":"SE Langford","year":"2007","journal-title":"AIDS Res Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of mk-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.","volume":"43","author":"M Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.","volume":"11","author":"G F\u00e4tkenheuer","year":"2005","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1086\/368164","article-title":"Determining the relative efficacy of highly active antiretroviral therapy.","volume":"187","author":"M Louie","year":"2003","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/JVI.78.4.1718-1729.2004","article-title":"Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.","volume":"78","author":"H Zhang","year":"2004","journal-title":"J Virol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.","volume":"44","author":"CJ Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/AAC.45.2.495-501.2001","article-title":"Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa\/CD4(+) cell clone 1\u201310 (magic-5).","volume":"45","author":"A Hachiya","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2165\/00003495-200363240-00005","article-title":"Enfuvirtide.","volume":"63","author":"TM Dando","year":"2003","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2165\/00003495-200767150-00010","article-title":"Maraviroc.","volume":"67","author":"NJ Carter","year":"2007","journal-title":"Drugs"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-200868010-00009","article-title":"Raltegravir.","volume":"68","author":"JD Croxtall","year":"2008","journal-title":"Drugs"},{"key":"ref20"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","article-title":"Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.","volume":"21","author":"JM Murray","year":"2007","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (mk-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"B Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"M Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00126839-200708030-00003","article-title":"HIV-1 integrase inhibitors: an emerging clinical reality.","volume":"8","author":"R Dayam","year":"2007","journal-title":"Drugs R D"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor gs-9137 (jtk-303) in treatment-naive and treatment-experienced patients.","volume":"43","author":"E DeJesus","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.","volume":"271","author":"AS Perelson","year":"1996","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy.","volume":"387","author":"AS Perelson","year":"1997","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.","volume":"373","author":"DD Ho","year":"1995","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1073\/pnas.94.13.6971","article-title":"Virus dynamics and drug therapy.","volume":"94","author":"S Bonhoeffer","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.272.5258.74","article-title":"Population dynamics of immune responses to persistent viruses.","volume":"272","author":"MA Nowak","year":"1996","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1073\/pnas.0711372105","article-title":"Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.","volume":"105","author":"AR Sedaghat","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350901400212","article-title":"Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.","volume":"14","author":"AR Sedaghat","year":"2009","journal-title":"Antivir Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1742-4690-2-66","article-title":"Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.","volume":"2","author":"SC Pettit","year":"2005","journal-title":"Retrovirology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JVI.72.4.2846-2854.1998","article-title":"Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.","volume":"72","author":"K Wiegers","year":"1998","journal-title":"J Virol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/MMBR.59.3.423-450.1995","article-title":"mRNA stability in mammalian cells.","volume":"59","author":"J Ross","year":"1995","journal-title":"Microbiol Rev"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation.","volume":"136","author":"J Houseley","year":"2009","journal-title":"Cell"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.","volume":"424","author":"B Mangeat","year":"2003","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.qai.0000220021.64115.37","article-title":"A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.","volume":"42","author":"MC Rosario","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2125.2008.03141.x","article-title":"A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.","volume":"65","author":"P Jacqmin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejps.2008.12.010","article-title":"Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.","volume":"36","author":"M von Kleist","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.","volume":"287","author":"DJ Hazuda","year":"2000","journal-title":"Science"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1021\/jm9801760","article-title":"Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.","volume":"41","author":"N Neamati","year":"1998","journal-title":"J Med Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1073\/pnas.092056199","article-title":"Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.","volume":"99","author":"JA Grobler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/mol.64.3.600","article-title":"Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (f185k\/c280s).","volume":"64","author":"C Marchand","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref46","first-page":"162","article-title":"Maturation inhibitors: a new therapeutic class targets the virus structure.","volume":"9","author":"K Salzwedel","year":"2007","journal-title":"AIDS Rev"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/JVI.69.6.3407-3419.1995","article-title":"The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity.","volume":"69","author":"HG Kr\u00e4usslich","year":"1995","journal-title":"J Virol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.68.12.8017-8027.1994","article-title":"The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.","volume":"68","author":"SC Pettit","year":"1994","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.2234683100","article-title":"PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in gag processing.","volume":"100","author":"F Li","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/JVI.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.","volume":"69","author":"LM Mansky","year":"1995","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/proc:2005001","article-title":"Exact simulation of hybrid stochastic and deterministic models for biochemical systems.","volume":"14","author":"A Alfonsi","year":"2005","journal-title":"ESAIM Proc"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1016599411804","article-title":"A brief history of R0 and a recipe for its calculation.","volume":"50","author":"JAP Heesterbeek","year":"2002","journal-title":"Acta Biotheor"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1098\/rsif.2005.0042","article-title":"Perspectives on the basic reproductive ratio.","volume":"2","author":"JM Heffernan","year":"2005","journal-title":"J R Soc Interface"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(99)02035-8","article-title":"Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.","volume":"354","author":"B Ramratnam","year":"1999","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1097\/00002030-199912030-00006","article-title":"Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.","volume":"13","author":"M Nijhuis","year":"1999","journal-title":"AIDS"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.1128\/JVI.70.11.7894-7899.1996","article-title":"Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.","volume":"70","author":"DV Havlir","year":"1996","journal-title":"J Virol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection.","volume":"373","author":"X Wei","year":"1995","journal-title":"Nature"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1128\/JVI.00683-09","article-title":"Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.","volume":"83","author":"C Goffinet","year":"2009","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.10269","article-title":"Replication capacity, biological phenotype, and drug resistance of hiv strains isolated from patients failing antiretroviral therapy.","volume":"69","author":"E Nicastri","year":"2003","journal-title":"J Med Virol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1137\/060663945","article-title":"Mathematical analysis of age-structured hiv-1 dynamics with combination antiretroviral therapy.","volume":"67","author":"L Rong","year":"2007","journal-title":"Siam J Appl Math"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1 dynamics in vivo.","volume":"41","author":"AS Perelson","year":"1999","journal-title":"SIAM Review"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1089\/cmb.2005.12.584","article-title":"Learning multiple evolutionary pathways from cross-sectional data.","volume":"12","author":"N Beerenwinkel","year":"2005","journal-title":"J Comput Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1086\/430005","article-title":"Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.","volume":"191","author":"N Beerenwinkel","year":"2005","journal-title":"J Infect Dis"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"e1000074","DOI":"10.1371\/journal.pcbi.1000074","article-title":"Viral population estimation using pyrosequencing.","volume":"4","author":"N Eriksson","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/QAD.0b013e3282fc972e","article-title":"Massively parallel pyrosequencing in HIV research.","volume":"22","author":"FD Bushman","year":"2008","journal-title":"AIDS"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-4690-6-15","article-title":"Massively parallel pyrosequencing highlights minority variants in the HIV-1 Env quasispecies deriving from lymphomonocyte sub-populations.","volume":"6","author":"G Rozera","year":"2009","journal-title":"Retrovirology"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e6079","DOI":"10.1371\/journal.pone.0006079","article-title":"Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.","volume":"4","author":"T Le","year":"2009","journal-title":"PLoS One"},{"key":"ref68","first-page":"447","article-title":"Numerical differentiation formulas for stiff systems of ordinary differential equations.","volume":"32","author":"R Klopfenstein","year":"1971","journal-title":"RCA Review"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1137\/S1064827594276424","article-title":"The matlab ode suite.","volume":"18","author":"L Shampine","year":"1997","journal-title":"SIAM Journal on Scientific Computing"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jtbi.2009.06.011","article-title":"Modeling HIV persistence, the latent reservoir, and viral blips.","volume":"260","author":"L Rong","year":"2009","journal-title":"J Theor Biol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-3565(24)37815-2","article-title":"Physiologically based pharmacokinetics of cyclosporine a: extension to tissue distribution kinetics in rats and scale-up to human.","volume":"287","author":"R Kawai","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10928-007-9071-3","article-title":"Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.","volume":"34","author":"M von Kleist","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/JVI.77.8.5037-5038.2003","article-title":"A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.","volume":"77","author":"M Markowitz","year":"2003","journal-title":"J Virol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"8518","DOI":"10.1128\/JVI.76.17.8518-8513.2002","article-title":"Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.","volume":"76","author":"TC Pierson","year":"2002","journal-title":"J Virol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/JVI.79.4.2199-2210.2005","article-title":"Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.","volume":"79","author":"Y Zhou","year":"2005","journal-title":"J Virol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/525283","article-title":"Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.","volume":"197","author":"KK Koelsch","year":"2008","journal-title":"J Infect Dis"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:23:54Z","timestamp":1739989434000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000720"}},"subtitle":[],"editor":[{"given":"Niko","family":"Beerenwinkel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,3,26]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1000720","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,26]]}}}